의료 관련 감염증 진단 시장 예측(2026-2032년)

The Healthcare-associated Infectious Disease Diagnostics Market is projected to grow by USD 49.77 billion at a CAGR of 8.75% by 2032.

Healthcare-associated infectious disease diagnostics are becoming central to patient safety, antimicrobial stewardship, infection prevention, and hospital quality performance. Healthcare-associated infections, including catheter-associated urinary tract infections, central line-associated bloodstream infections, ventilator-associated pneumonia, surgical site infections, Clostridioides difficile infection, and multidrug-resistant organism transmission, continue to challenge acute care hospitals, long-term care facilities, ambulatory surgery centers, and diagnostic laboratories. The executive priority is shifting from reactive testing to rapid, integrated, and risk-based diagnostic workflows that identify pathogens, resistance markers, and transmission risks earlier in the care pathway. Demand is being shaped by rising hospital-acquired infection surveillance requirements, expanding molecular diagnostics adoption, increased awareness of antimicrobial resistance, and the need for faster clinical decisions in high-risk settings such as intensive care units, oncology wards, transplant units, and neonatal care. Core technologies include culture-based microbiology, immunoassays, nucleic acid amplification tests, syndromic panels, mass spectrometry, sequencing, and digital surveillance platforms. The strongest value proposition lies in reducing time to actionable results, improving isolation decisions, supporting targeted antimicrobial therapy, and strengthening compliance with infection control standards. For industry stakeholders, success depends on clinical accuracy, workflow compatibility, cost-effectiveness, interoperability with hospital information systems, and evidence demonstrating measurable improvements in patient outcomes and infection prevention performance.

Transformative Shifts in the Diagnostic Landscape

The healthcare-associated infectious disease diagnostics landscape is undergoing a structural transformation driven by faster testing modalities, decentralized access, and stronger links between diagnostics and infection prevention programs. Traditional culture remains essential for organism recovery, susceptibility testing, and epidemiological investigation, but hospitals are increasingly complementing it with molecular assays and rapid phenotypic tools to shorten time to pathogen identification and resistance detection. Syndromic testing is helping clinicians evaluate complex infections where multiple bacterial, viral, or fungal causes may be present, while sequencing is supporting outbreak investigation and strain-level surveillance. Another major shift is the movement from laboratory-only testing toward near-patient and point-of-care workflows for selected use cases, particularly where rapid isolation, cohorting, or treatment escalation decisions are needed. Diagnostic stewardship is also becoming a defining theme, as healthcare systems seek to ensure the right test is used for the right patient at the right time, minimizing false positives, unnecessary treatment, and avoidable costs. Regulatory expectations, hospital accreditation pressures, and public reporting of infection indicators are reinforcing demand for validated, reproducible, and interoperable diagnostic solutions. At the same time, antimicrobial resistance is elevating the importance of resistance gene detection, local antibiogram integration, and faster susceptibility insights. The market environment is therefore moving toward integrated diagnostic ecosystems that combine laboratory excellence, real-time data exchange, and infection control intelligence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding a cumulative layer of intelligence across healthcare-associated infectious disease diagnostics by enhancing test selection, result interpretation, surveillance, and operational decision-making. In clinical microbiology laboratories, AI-enabled image analysis can support faster screening of culture plates, Gram stain interpretation, and colony recognition, while machine learning models can help prioritize specimens or flag unusual resistance patterns for expert review. In hospital infection prevention, AI can combine laboratory results, admission data, device utilization, antibiotic exposure, bed movement, and electronic health record signals to identify clusters, predict outbreak risk, and support early intervention. Natural language processing can extract infection-relevant information from clinical notes and operative reports, improving case detection and surveillance completeness. AI also strengthens antimicrobial stewardship by linking diagnostic outputs with patient-specific factors and local resistance trends to support more targeted therapy recommendations. The impact is cumulative because value increases when AI is embedded across the entire workflow: pre-analytical triage, analytical quality control, post-analytical interpretation, and population-level surveillance. However, adoption depends on transparent validation, explainability, cybersecurity safeguards, bias monitoring, and alignment with clinical governance. Healthcare organizations are prioritizing AI tools that integrate with existing laboratory information systems and electronic health records, generate auditable recommendations, and demonstrate practical benefits such as shorter turnaround times, improved outbreak detection, reduced unnecessary testing, and better antimicrobial utilization.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

Asia-Pacific is witnessing expanding use of rapid diagnostics as large hospital networks, growing surgical volumes, and rising awareness of antimicrobial resistance increase the need for faster infection detection, with China, India, Japan, South Korea, and Australia investing in laboratory modernization and surveillance capacity. North America remains highly advanced in healthcare-associated infection monitoring, supported by established hospital reporting systems, antimicrobial stewardship programs, molecular testing adoption, and strong integration of diagnostic data into electronic health records. Latin America is strengthening diagnostic access through public health laboratory improvements and hospital infection control initiatives, with Brazil and Mexico emphasizing capacity expansion amid persistent challenges related to resource variability and antimicrobial resistance surveillance. Europe is characterized by mature infection prevention frameworks, cross-border antimicrobial resistance monitoring, and strong uptake of quality-assured laboratory testing, with European health systems placing increasing emphasis on standardized surveillance and diagnostic stewardship. The Middle East is advancing hospital infrastructure, accreditation-led infection control, and laboratory automation, particularly in GCC health systems where tertiary care expansion and medical tourism support demand for rapid and reliable diagnostics. Africa faces the dual challenge of high infectious disease burden and uneven laboratory capacity, but regional progress is visible through antimicrobial resistance action plans, infection prevention programs, and investments in molecular testing, reference laboratories, and outbreak surveillance. Across all regions, the common growth drivers are patient safety mandates, antimicrobial resistance containment, surgical and intensive care expansion, and the need for real-time diagnostic intelligence in healthcare facilities.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are prioritizing healthcare-associated infection diagnostics as regional health systems expand hospital infrastructure, strengthen infection prevention programs, and respond to antimicrobial resistance threats across both public and private care settings. The GCC is advancing rapidly through hospital accreditation, digital health investment, advanced laboratory automation, and stewardship initiatives that align diagnostics with quality improvement and patient safety objectives. The European Union benefits from coordinated surveillance structures, antimicrobial resistance monitoring, medical device regulation, and cross-country public health collaboration, making standardization, data interoperability, and diagnostic quality central priorities. BRICS economies represent a diverse but influential group where large patient populations, expanding tertiary care, national antimicrobial resistance strategies, and domestic diagnostic capacity development are increasing the relevance of rapid and scalable testing approaches. G7 countries generally demonstrate high diagnostic adoption, strong laboratory networks, and mature stewardship policies, with ongoing emphasis on reducing hospital-onset infections, improving turnaround times, and integrating diagnostics into digital care pathways. NATO countries include many health systems with advanced biodefense, emergency preparedness, and infection surveillance priorities, supporting demand for resilient diagnostic infrastructure that can address routine hospital infections as well as outbreak and preparedness scenarios. Across these groups, the strongest opportunities are linked to harmonized surveillance, procurement modernization, laboratory workforce development, diagnostic stewardship, and validated technologies that can be implemented across complex health systems.

Key Country Insights Across Major Healthcare Markets

The United States has a highly developed healthcare-associated infection surveillance environment, with strong emphasis on hospital reporting, antimicrobial stewardship, and rapid molecular diagnostics for high-risk care settings. Canada focuses on patient safety, antimicrobial resistance monitoring, and coordinated infection prevention practices across provincial healthcare systems. Mexico is expanding diagnostic capacity as hospital networks address infection control needs and antimicrobial resistance surveillance gaps. Brazil is a major Latin American market for hospital infection diagnostics due to its large healthcare system, reference laboratory infrastructure, and ongoing antimicrobial resistance initiatives. The United Kingdom emphasizes national surveillance, diagnostic stewardship, and infection prevention standards across hospitals, while Germany combines advanced laboratory infrastructure with strong microbiology and hospital quality systems. France continues to prioritize antimicrobial stewardship and infection surveillance, supported by structured healthcare quality programs, and Russia is advancing diagnostic capacity across large hospital networks while addressing regional variability in laboratory access. Italy and Spain maintain strong hospital microbiology capabilities and infection control programs, with continuing attention to surgical site infections, multidrug-resistant organisms, and C. difficile management. China is investing heavily in hospital modernization, molecular diagnostics, and antimicrobial resistance control as tertiary hospitals expand advanced testing capacity. India is strengthening infection prevention and diagnostic access through national antimicrobial resistance initiatives, growing private hospital networks, and increasing molecular testing adoption. Japan has a mature diagnostics environment with advanced hospital laboratories, aging-population care needs, and strong quality standards. Australia emphasizes national antimicrobial resistance surveillance, infection prevention guidelines, and high-quality laboratory networks, while South Korea combines advanced digital health infrastructure, hospital accreditation, and strong molecular diagnostics adoption. Across these countries, adoption patterns differ by reimbursement, laboratory maturity, workforce capacity, and regulatory pathways, but all share a common need for faster, accurate, and actionable diagnostics to reduce healthcare-associated infection risks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize solutions that align rapid diagnostics with infection prevention, antimicrobial stewardship, and hospital workflow efficiency. Product strategies should focus on clinically validated assays that deliver actionable pathogen identification and resistance insights within timeframes that influence treatment, isolation, and device-management decisions. Developers should strengthen interoperability with laboratory information systems, electronic health records, surveillance platforms, and antimicrobial stewardship dashboards to make diagnostic results usable at the point of care. Commercial teams should build evidence packages around patient outcomes, reduced time to optimal therapy, improved outbreak detection, lower unnecessary antimicrobial exposure, and operational efficiency rather than relying only on analytical performance claims. Organizations should also support diagnostic stewardship by providing clear use criteria, interpretation guidance, and education for clinicians, microbiologists, pharmacists, and infection preventionists. Regional strategies should account for differences in reimbursement, regulatory requirements, laboratory infrastructure, and workforce capacity, with scalable models for both high-throughput central laboratories and decentralized care settings. AI-enabled solutions should be deployed with transparent validation, cybersecurity protections, and clinical governance frameworks. Partnerships with hospitals, public health agencies, academic centers, and reference laboratories can accelerate real-world validation and adoption. Above all, industry leaders should position healthcare-associated infectious disease diagnostics as a patient safety and antimicrobial resistance mitigation tool, not merely as a laboratory product category.

Research Methodology

This executive summary is built on a structured secondary research approach using verified public health, clinical, regulatory, and industry-relevant sources. The analysis draws on evidence from hospital infection prevention guidelines, antimicrobial resistance action plans, healthcare quality reporting frameworks, peer-reviewed clinical literature, public health surveillance programs, regulatory publications, and laboratory medicine standards. The methodology emphasizes triangulation across multiple credible sources to identify consistent themes in diagnostic adoption, technology evolution, regional priorities, and healthcare system needs. Qualitative assessment was used to evaluate the role of culture-based diagnostics, molecular testing, immunoassays, sequencing, mass spectrometry, digital surveillance, and AI-enabled decision support in healthcare-associated infection management. Regional, group, and country insights were developed by reviewing healthcare infrastructure maturity, infection prevention priorities, antimicrobial resistance policies, laboratory capacity, and digital health readiness. The analysis deliberately excludes market sizing, market share, and forecasting, focusing instead on data-backed industry dynamics, clinical drivers, regulatory context, and strategic implications. Keywords and terminology were selected to align with healthcare-associated infection diagnostics, hospital-acquired infection testing, antimicrobial resistance diagnostics, infection prevention, molecular diagnostics, diagnostic stewardship, and clinical microbiology workflows while preserving accuracy and readability.

Conclusion

Healthcare-associated infectious disease diagnostics are entering a more integrated, data-driven, and clinically actionable era. The central challenge for healthcare systems is no longer only detecting pathogens, but doing so quickly enough to guide isolation, therapy, outbreak control, and antimicrobial stewardship decisions. Rapid molecular diagnostics, advanced microbiology workflows, sequencing, digital surveillance, and artificial intelligence are reshaping how hospitals identify and manage healthcare-associated infections. Regional momentum is strongest where infection prevention mandates, laboratory modernization, and antimicrobial resistance policies converge, but the need for reliable diagnostics is universal across advanced and emerging health systems. Future competitiveness will depend on clinical validation, workflow integration, affordability, interoperability, and evidence that diagnostic tools improve patient safety outcomes. Organizations that connect accurate testing with stewardship, surveillance, and real-time decision support will be best positioned to address the growing burden of healthcare-associated infections and multidrug-resistant organisms. In this environment, diagnostics serve as a strategic pillar of modern healthcare quality, enabling earlier intervention, better resource use, and stronger protection for patients, clinicians, and health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method

• 7.1. Introduction
• 7.2. Immunoassays
  • 7.2.1. Chemiluminescent Immunoassay
  • 7.2.2. ELISA
  • 7.2.3. Lateral Flow Assays
• 7.3. Microbiology
  • 7.3.1. Culture
    • 7.3.1.1. Aerobic Culture
    • 7.3.1.2. Anaerobic Culture
  • 7.3.2. Microscopy
  • 7.3.3. Sensitivity Testing
• 7.4. Molecular Diagnostics
  • 7.4.1. Isothermal Amplification
  • 7.4.2. PCR
  • 7.4.3. Sequencing

8. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type

• 8.1. Introduction
• 8.2. Bacterial
  • 8.2.1. Clostridium Difficile
  • 8.2.2. Escherichia Coli
  • 8.2.3. Pseudomonas Aeruginosa
  • 8.2.4. Staphylococcus Aureus
• 8.3. Fungal
  • 8.3.1. Aspergillus Species
  • 8.3.2. Candida Species
  • 8.3.3. Cryptococcus Neoformans
• 8.4. Parasitic
  • 8.4.1. Malaria Parasites
  • 8.4.2. Toxoplasma Gondii
• 8.5. Viral
  • 8.5.1. Coronavirus
  • 8.5.2. Influenza Virus
  • 8.5.3. Norovirus
  • 8.5.4. Respiratory Syncytial Virus

9. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type

• 9.1. Introduction
• 9.2. Blood
  • 9.2.1. Serum
  • 9.2.2. Whole Blood
• 9.3. Cerebrospinal Fluid
• 9.4. Respiratory
  • 9.4.1. Bronchoalveolar Lavage
  • 9.4.2. Nasopharyngeal Swabs
  • 9.4.3. Sputum
• 9.5. Urine
  • 9.5.1. Catheterized Urine
  • 9.5.2. Midstream Urine
• 9.6. Wound Swabs
  • 9.6.1. Deep Tissue Samples
  • 9.6.2. Surface Swabs

10. Healthcare-associated Infectious Disease Diagnostics Market, by End User

• 10.1. Introduction
• 10.2. Diagnostic Laboratories
  • 10.2.1. Independent Laboratories
  • 10.2.2. Reference Laboratories
• 10.3. Hospitals
  • 10.3.1. Clinical Pathology Laboratories
  • 10.3.2. Microbiology Laboratories
• 10.4. Point Of Care
  • 10.4.1. Clinics
  • 10.4.2. Emergency Departments
  • 10.4.3. Long Term Care Facilities

11. Healthcare-associated Infectious Disease Diagnostics Market, by Application

• 11.1. Introduction
• 11.2. Screening
• 11.3. Diagnosis
• 11.4. Monitoring
• 11.5. Surveillance

12. Healthcare-associated Infectious Disease Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Healthcare-associated Infectious Disease Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Healthcare-associated Infectious Disease Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Accelerate Diagnostics Inc
• 16.3. Agilent Technologies Inc
• 16.4. Bio-Rad Laboratories Inc
• 16.5. bioMerieux SA
• 16.6. Co-Diagnostics Inc
• 16.7. Danaher Corporation
• 16.8. DiaSorin S.p.A.
• 16.9. F. Hoffmann-La Roche Ltd
• 16.10. Genetic Signatures Ltd
• 16.11. Grifols S.A.
• 16.12. Hologic Inc
• 16.13. Illumina Inc
• 16.14. Labcorp Holdings Inc
• 16.15. Luminex Corporation
• 16.16. Merck KGaA
• 16.17. Meridian Bioscience Inc
• 16.18. Natera Inc
• 16.19. OpGen Inc
• 16.20. OraSure Technologies Inc
• 16.21. QIAGEN N.V.
• 16.22. QuidelOrtho Corporation
• 16.23. Revvity Inc
• 16.24. SD Biosensor Inc
• 16.25. Seegene Inc
• 16.26. Siemens Healthineers AG
• 16.27. Sysmex Corporation
• 16.28. Thermo Fisher Scientific Inc
• 16.29. Trinity Biotech PLC